Navigation Links
Neurotrope, Inc., to Present at Biotech Showcase 2014 in San Francisco
Date:1/6/2014

PLANTATION, Fla., Jan. 6, 2014 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) (the "Company") announced today that the Company will present at the Biotech Showcase 2014 conference 8:00AM Pacific Time on Monday, January 13, 2014 at the Parc 55 Wyndham Hotel, Union Square in San Francisco, California.

The Company will discuss its unique position as it works towards commercializing certain technologies that were initially developed by the Blanchette Rockefeller Neurosciences Institute and its affiliates, for the diagnosis of and treatment of Alzheimer's Disease.  The Company's core research program is targeted towards developing novel therapeutic modalities to treat a variety of neurodegenerative pathologies. Details of the Company's initiatives for 2014 will also be provided.

Neurotrope, Inc. will webcast its corporate presentation at:
http://www.media-server.com/m/p/qegzumcw

The webcast may also be accessed on the Company's website, www.neurotropebioscience.com.  The webcast can be accessed live and will be available for replay after the presentation on the Company's website.

About Biotech Showcase

Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year.

About Neurotrope

Neurotrope was formed in October 2012 to develop and market two product platforms, includi
'/>"/>

SOURCE Neurotrope, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurotrope, Inc., Announces New Trading Symbol
2. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
3. AquaLiv Technologies, Inc. and Its Subsidiary, AquaLiv, Inc., Release Funding Updates
4. Agility Clinical, Inc., a Specialty Contract Research Organization is Formed
5. Pinnaclife, Inc., Announces NDC, Inc., to Exclusively Distribute the New Animal Health Product Line!
6. Sanguine Appoints Darlene Rosario, Vice President of Regulatory Affairs & Quality at Biothera, Inc., to Clinical Advisory Board and Ethics Committee
7. Genomatica, Inc., Award-Winning Industrial Biotechnology Pioneer, Selects Alexandria Real Estate Equities, Inc. for Long-Term, Mission-Critical R&D Facility and Corporate Headquarters
8. Free Research Report on Dyax Corp., Ebix, Inc., 8x8, Inc., EnerSys and Express Scripts Holding Co.
9. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
10. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
11. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... Northwest,Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; ... today that Lonza Group AG has,withdrawn all ... and other NWBT DCVax(R) products other than ... vaccine products infringed,certain gene expression technology patents ...
... offers substance abuse treatment for teens and adults, ... has announced the expansion of its treatment services to,include ... 12 - 17 as well,as adults, and the hospital ... health and dual diagnosis (substance abuse and,mental illness)., ...
... ALTO, Calif., Dec. 19 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... Barron, MD, FACC to its Board of Directors. Dr. ... Officer at Genentech,where he leads the Development organization, which ... Barron joined Genentech in 1996 as a clinical scientist ...
Cached Biology Technology:Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics 2Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics 3Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics 4Highlands Behavioral Health Hospital Unveils New Substance Abuse Detox Program 2Alexza Elects Dr. Hal V. Barron to Its Board of Directors 2Alexza Elects Dr. Hal V. Barron to Its Board of Directors 3
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
(Date:10/16/2014)... researchers have challenged conventional thinking on how the bowel ... mechanism for how bowel cancer starts. , The researchers ... and regenerating the ,crypts, that are a feature of ... involved in bowel cancer development, a controversial finding as ... , Using 3D imaging technologies, Dr Chin Wee Tan ...
(Date:10/16/2014)... 16, 2014) – Post-menopausal women experienced improvements in ... levels or genital bleeding, after 12 weeks of ... fermented soy germ-based nutritional supplement previously shown to ... new peer-reviewed pilot study reported in a poster ... scientific meeting. , "These data documented improved ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... By manipulating highly specific gene-regulating molecules called microRNAs, scientists at ... in singling out and repressing stem-like cells in mouse breast ... to cancer. If certain forms of breast cancer do ... believe to be the case, then it is critical to ...
... induce cells to form parallel tube-like structures that could one ... found that they can control the cells, development by growing ... the work was posted this month in an online issue ... day be transplanted into tissues such as the kidneys, liver, ...
... events that are critical to a healthy life, giving ... to think. But thats if the neurotransmitters are getting ... cells, neurons or other cells. Now a ... transcription factor that controls a neurotransmitter in the nematode ...
Cached Biology News:CSHL scientists identify and repress breast cancer stem cells in mouse tissue 2CSHL scientists identify and repress breast cancer stem cells in mouse tissue 3MIT works toward engineered blood vessels 2Overexcited neurons not good for cell health 2Overexcited neurons not good for cell health 3
Human Xg Affinity Purified Polyclonal Ab Keywords: Xg glycoprotein, hereditary hemorrhagic telangiectasia Protein Family: ...
nuclear RNA export factor 1, mRNA...
Mycoplasma tested...
Human PDGF, CF...
Biology Products: